芦可替尼治疗西达基奥仑赛相关难治性腹泻
本文报告5例多发性骨髓瘤患者在接受BCMA CAR-T(西达基奥仑赛)后出现严重腹泻,其中3例接受芦可替尼治疗均获快速临床改善;2例有配对活检者均显示组织病理学缓解,包括1例CAR-T相关胃肠道惰性T细胞淋巴增殖性疾病。
要点
- BCMA CAR-T后难治性腹泻死亡率达36%–50%,临床管理未知
- 芦可替尼可能对CAR-T相关免疫驱动性腹泻有效
- 配对活检显示组织病理学缓解,支持生物学合理性
核心结论
- 芦可替尼可使BCMA CAR-T相关严重腹泻患者获得快速临床改善和组织病理学缓解。
研究设计与样本
- 病例系列,报告5例接受BCMA CAR-T(西达基奥仑赛)后出现严重腹泻的多发性骨髓瘤患者。
主要发现
- 3例接受芦可替尼治疗的患者均出现快速临床改善。
- 2例有匹配治疗前后活检的患者均显示组织病理学缓解迹象。
- 其中1例活检显示CAR-T相关胃肠道惰性T细胞淋巴增殖性疾病。
关键数值与推荐
- BCMA CAR-T相关难治性腹泻的 reported 死亡率为36%至50%。
临床怎么用
- 对于BCMA CAR-T后严重腹泻,可考虑芦可替尼作为治疗选择,但需更多证据验证。
局限性
- 样本量小(5例),仅3例接受芦可替尼,缺乏对照,结论需前瞻性研究验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Intractable diarrhea is a recently described complication following B-cell maturation antigen (BCMA)-targeted chimeric antigen receptor (CAR) T-cell therapy for multiple myeloma with reported mortality rates of 36% to 50%. The optimal clinical management is unknown. Here, we report a series of 5 patients who presented with severe diarrhea after BCMA CAR T-cell treatment. We hypothesized that the Janus kinase inhibitor, ruxolitinib, might be an effective therapy based on its success in graft-versus-host-disease after allogeneic bone marrow transplant and other immune-driven diarrhea syndromes. Three patients received ruxolitinib, all of whom experienced rapid clinical improvement. Among the 2 patients with matched pretreatment and posttreatment biopsies, both showed signs of histopathologic response, including 1 with CAR T-cell-associated indolent T-cell lymphoproliferative disease of the gastrointestinal tract.
引用
- Blumenberg V, Birocchi F, Shih A, et al. Ruxolitinib for ciltacabtagene autoleucel-associated refractory diarrhea. Blood. 2026. PMID: 41592291. doi:10.1182/blood.2025032347
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。